Alambic Investment Management’s Corcept Therapeutics CORT Stock Holding History

Alambic Investment Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-15,323	Closed	-$267K	–	10
2020 Q3	$267K	Sell	15,323 -14,524	-49%	-$231K	2.93%	10
2020 Q2	$502K	Buy	29,847 +300	+1%	+$4.21K	1.26%	14
2020 Q1	$351K	Sell	29,547 -12,926	-30%	-$160K	0.85%	39
2019 Q4	$514K	Buy	+42,473	New	+$591K	0.43%	85
2019 Q2	–	Sell	-28,500	Closed	-$335K	–	314
2019 Q1	$335K	Buy	+28,500	New	+$354K	0.14%	215
2017 Q2	–	Sell	-18,800	Closed	-$206K	–	583
2017 Q1	$206K	Sell	18,800 -5,200	-22%	-$45.7K	0.03%	570
2016 Q4	$174K	Sell	24,000 -4,300	-15%	-$33.7K	0.03%	513
2016 Q3	$184K	Buy	28,300 +11,400	+67%	+$66.3K	0.04%	438
2016 Q2	$92K	Buy	+16,900	New	+$87.9K	0.02%	498

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Alambic Investment Management's CORT Position: Q4 2020 in Review

Alambic Investment Management sold out of Corcept Therapeutics (CORT) in Q4 2020, closing a stake of 15,323 shares — an estimated $267K sold.

Alambic Investment Management first reported a position in CORT in Q2 2016 and held it in 9 quarters. The position peaked at $514K in Q4 2019. 226 funds tracked by Wall St. Rank hold CORT as of Q4 2020.

Alambic Investment Management reported no remaining Corcept Therapeutics position as of Q4 2020 after selling out during the quarter.
Alambic Investment Management sold 15,323 Corcept Therapeutics shares in Q4 2020, an estimated $267K.
Alambic Investment Management first reported a position in Corcept Therapeutics in Q2 2016 and held it in 9 quarters.
Alambic Investment Management's Corcept Therapeutics position peaked at $514K in Q4 2019.
226 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2020.

Based on Alambic Investment Management's 13F filing for Q4 2020.